BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma
Status:
NOT_YET_RECRUITING
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to explore the real-world Chinese relapsed/refractory patients to evaluate the efficacy and safety of BV monotherapy or combination therapy in CHL patients. The main questions it aims to answer are:
To evaluate the efficacy and toxicity of BV-containing regimen in relapsed/refractory CHL patients in China, and to provide reference for the rational and safe use of BV in clinical practice.